Browsing Tag
PROTAC
3 posts
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology
General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery.
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.